Finance

Lists
BIIB34:BVMF
Biogen Inc BDR
၁၈၆.၀၁ R$
၀.၀၀%
(၀.၀၀) 1D
အောက် ၉, GMT-၃ ၁၆:၅၆:၀၀  ·   BRL
All symbols
SymbolPriceChange% Change
Generating top insights for BIIB34...
Open
၁၈၆.၀၁ R$
High
၁၈၆.၀၁ R$
Low
၁၈၆.၀၁ R$
Mkt. cap
ဋေ ၃.၃၃ ထ
Avg. vol.
၇.၀၀
Volume
၁.၀၀
52-wk high
၁၉၁.၀၀ R$
52-wk low
၁၂၈.၆၉ R$
Shares outstanding
၁၄.၇၈ ကုဋေ
No. of employees
၈ ထောင်
Open
၁၈၆.၀၁ R$
High
၁၈၆.၀၁ R$
Low
၁၈၆.၀၁ R$
Mkt. cap
ဋေ ၃.၃၃ ထ
Avg. vol.
၇.၀၀
Volume
၁.၀၀
52-wk high
၁၉၁.၀၀ R$
52-wk low
၁၂၈.၆၉ R$
Shares outstanding
၁၄.၇၈ ကုဋေ
No. of employees
၈ ထောင်
News stories
From web sources and news partners
Profile
Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, United States specializing in the treatment of neurological diseases. The company's primary products are dimethyl fumarate, diroximel fumarate, interferon beta-1a, peginterferon beta-1a, and natalizumab, all for the treatment of multiple sclerosis; nusinersen for the treatment of spinal muscular atrophy; omaveloxolone for the treatment of Friedreich's ataxia; tofersen for the treatment of ALS; and dimethyl fumarate for the treatment of severe plaque psoriasis. The company also produces 5 biosimilars and has collaborations with Genentech for several drugs. The company is ranked 424th on the Fortune 500 and 845th on the Forbes Global 2000. Wikipedia
About Biogen Inc BDR
CEOChris Viehbacher
Employees၇.၅ ထောင်
Founded၁၉၇၈
Headquartersကင်းဘရစ်ချ်, မက်ဆာချူးဆက်ပြည်နယ်, ယူနိုက်တက်စတိတ်
Sector-
Websitebiogen.com
Last report
၂၀၂၆ ဇူ ၂၉
Fiscal period
Q2 2026
၃.၆၀ US$ / ၂.၀၃ US$
+၇၇.၃၈%beat
Revenue / Est. (USD)
၂၇၃.၆၀ ဋေ / ၂၄၆.၀၆ ဋေ
+၁၁.၁၉%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
၂၀၂၅ စက်
၂၀၂၅ ဒီ
၂၀၂၆ မတ်
၂၀၂၆ ဇွန်
Revenue
၂၅၃.၄၇ ဋေ
၂၂၇.၉၄ ဋေ
၂၄၇.၇၈ ဋေ
၂၇၃.၆၀ ဋေ
Cost of goods sold
၅၀.၈၆ ကုဋေ
၄၄.၃၄ ကုဋေ
၆၁.၀၂ ကုဋေ
၆၁.၁၆ ကုဋေ
Cost of revenue
၅၀.၈၆ ကုဋေ
၄၄.၃၄ ကုဋေ
၆၁.၀၂ ကုဋေ
၆၁.၁၆ ကုဋေ
Research and development expenses
၄၃.၁၈ ကုဋေ
၄၇.၇၁ ကုဋေ
၄၈.၂၂ ကုဋေ
၄၉.၂၁ ကုဋေ
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
၅၉.၂၈ ကုဋေ
၆၈.၅၂ ကုဋေ
၆၀.၇၃ ကုဋေ
၇၀.၉၇ ကုဋေ
Operating expense
၁၂၄.၇၅ ဋေ
၁၃၆.၄၄ ဋေ
၁၃၀.၀၂ ဋေ
၁၄၃.၈၈ ဋေ
Total operating expenses
၁၇၅.၆၁ ဋေ
၁၈၀.၇၈ ဋေ
၁၉၁.၀၄ ဋေ
၂၀၅.၀၄ ဋေ
Operating income
၇၇.၈၆ ကုဋေ
၄၇.၁၆ ကုဋေ
၅၆.၇၄ ကုဋေ
၆၈.၅၆ ကုဋေ
Other non operating income
၁.၅၈ ကုဋေ
၁.၇၄ ကုဋေ
-၁.၁၀ သန်း
၃.၀၀ သန်း
EBT including unusual items
၅၅.၇၃ ကုဋေ
-၅.၆၀ ကုဋေ
၃၇.၇၇ ကုဋေ
၁၃.၂၄ ကုဋေ
EBT excluding unusual items
၇၄.၈၃ ကုဋေ
၄၄.၇၀ ကုဋေ
၅၃.၀၁ ကုဋေ
၆၂.၅၁ ကုဋေ
Income tax expense
၉.၀၈ ကုဋေ
-၇.၁၀ သန်း
၅.၈၂ ကုဋေ
၃.၄၉ ကုဋေ
Effective tax rate
၁၆.၂၉%
၁၂.၆၈%
၁၅.၄၁%
၂၆.၃၆%
Other operating expenses
၈.၇၂ ကုဋေ
၆.၉၉ ကုဋေ
၇.၄၂ ကုဋေ
၆.၈၈ ကုဋေ
Net income
၄၆.၆၅ ကုဋေ
-၄.၈၉ ကုဋေ
၃၁.၉၅ ကုဋေ
၉.၇၅ ကုဋေ
Net profit margin
၁၈.၄၀%
-၂.၁၅%
၁၂.၈၉%
၃.၅၆%
Earnings per share
၄.၈၁
၁.၉၉
၃.၅၇
၃.၆၀
Interest and investment income
၃.၁၆ ကုဋေ
၃.၇၂ ကုဋေ
၃.၇၉ ကုဋေ
၂.၅၃ ကုဋေ
Interest expense
-၆.၇၄ ကုဋေ
-၆.၇၅ ကုဋေ
-၆.၇၆ ကုဋေ
-၈.၂၃ ကုဋေ
Net interest expenses
-၃.၅၈ ကုဋေ
-၃.၀၃ ကုဋေ
-၂.၉၇ ကုဋေ
-၅.၇၀ ကုဋေ
Depreciation and amortization charges
-
-
-
-
EBITDA
၉၈.၀၈ ကုဋေ
၆၇.၁၈ ကုဋေ
၇၇.၁၈ ကုဋေ
၉၂.၁၇ ကုဋေ
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
Google အက်ပ်များ